Novo Nordisk’s GLP-1 Franchise Buoyed By SUSTAIN FORTE data

Showed Superior Diabetes Risk-Benefit From Higher Ozempic Dose

 
• By Sten Stovall
  
SUSTAIN FORTE Compared Investigational 2.0mg dose of semaglutide to 1.0mg • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D